Abstract: Disclosed herein are related to a circuit and a method of reading or sensing multiple bits of data stored by a multi-level cell. In one aspect, a first reference circuit is selected from a first set of reference circuits, and a second reference circuit is selected from a second set of reference circuits. Based at least in part on the first reference circuit and the second reference circuit, one or more bits of multiple bits of data stored by a multi-level cell can be determined. According to the determined one or more bits, a third reference circuit from the first set of reference circuits and a fourth reference circuit from the second set of reference circuits can be selected. Based at least in part on the third reference circuit and the fourth reference circuit, additional one or more bits of the multiple bits of data stored by the multi-level cell can be determined.

Abstract: Described herein are modulators of TNF alpha activity and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of TNF alpha-mediated disorders or diseases.

Abstract: An ophthalmic preparation of a tyrosine kinase inhibitor suitable for eye drop administration is prepared from the following active ingredients and adjuvants in parts by weight: active ingredient: 0.5-1.5 parts of tyrosine kinase inhibitor, wherein the content of the active ingredient in the ophthalmic preparation is 0.1-1 mg/mL; and pharmaceutically acceptable adjuvants: 200-300 parts of the surfactant, 0.5-7.0 parts of the tackifier, 10-800 parts of the solubilizer, with the balance being solvent. The ophthalmic preparation can effectively deliver the active ingredient to the fundus oculi to treat fundus angiogenesis diseases, with high absorption and utilization rate, small particle size and good stability, which are suitable for preparing sterile preparation by means of microporous filter membrane sterilization method and/or high-temperature sterilization method.

Abstract: A carrier or auxiliary material of an ophthalmic preparation, a preparation method therefor, and an application thereof, relating to the field of ophthalmic drug delivery. The carrier or auxiliary material of the ophthalmic preparation contains components such as a surfactant and an ionic polymer, and also contains a solvent. Or, the carrier or auxiliary material of the ophthalmic preparation contains components of low-polymerization-degree povidone and medium-polymerization-degree povidone, and also contains a solvent. Spherical nanobodies are formed in the solvent by the component contained in the carrier or auxiliary material of the ophthalmic preparation, have a particle size of 1-100 nm, and can be self-assembled to form spherical nanospheres having a particle size of 10-2000 nm. The administration carrier can wrap a drug through an anterior segment to efficiently deliver the drug to a posterior segment to play a therapeutic action.

Abstract: An ophthalmic formulation for preventing and treating cataracts contains an active substance for treating eye diseases and a pharmaceutically acceptable carrier or excipient. The active substance is oxidized cholesterol, including lanosterol or 25-hydroxycholesterol; the pharmaceutically acceptable carrier or excipient contains a surfactant, a tackifier, a cosolvent, and a solvent; the content of the oxidized cholesterol in the formulation is 0.01-5 mg/mL; and the mass ratio of the surfactant, the tackifier, the cosolvent, and the oxidized cholesterol is (1-300):(1-100):(100-3000):1, with the balance being the solvent. Upon eye drop administration, the formulation can cause the active substance to be selectively enriched in the lens of a laboratory animal to accurately exert the effect of treating cataracts. The active substance is not distributed in the aqueous humor and the vitreous body, thereby avoiding toxic and side effects on other eye tissue and the whole body.

Abstract: Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

Abstract: Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.

Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

Abstract: Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.

Abstract: An ophthalmic preparation is effective for preventing and treating dry macular degeneration and retinal light damage. The preparation includes an active ingredient for treating an ocular disease and an ophthalmic preparation carrier or adjuvant. The active ingredient for treating the ocular disease is an adenylate-activated protein kinase activator and/or an anti-inflammatory active ingredient. The ophthalmic preparation carrier or adjuvant contains the following components: a surfactant, an ionic macromolecule, and a solvent. The ophthalmic preparation can be administered by eye drops for carrying (wrapping) the adenylate-activated protein kinase activator and/or the anti-inflammatory active ingredient through the anterior eye segment, and delivering same to a posterior eye segment for preventing and treating dry macular degeneration and retinal light damage.

Abstract: Described herein are ?4?7 integrin inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of ?4?7 integrin-mediated conditions, such as inflammatory bowel disease (IBD), ulcerative colitis (UC), and Crohn's disease (CD).

Abstract: Described herein are compounds, for example, 1,2,4-triazole-substituted N-heteroaryl amines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Abstract: Described herein are compounds, for example, substituted pyridazines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Abstract: Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors.

Abstract: A system includes a plurality of sensors configured to sense an opening/closing of a door, fastening/unfastening of a seat safety belt, and change in a vehicle height; a first processor configured to determine the number of all occupants in the vehicle by the opening/closing of the door, the fastening/unfastening of the seat safety belt, and the change in the vehicle height sensed by the plurality of sensors and preliminarily determine an internal circulation ratio of the air conditioning system according to the determined number of all occupants in the vehicle; a second processor configured to adjust the internal circulation ratio which is preliminarily determined by the first processor according to at least one of a sound intensity and a sound duration time in the vehicle; and a controller configured to control the air conditioning system according to the adjusted internal circulation ratio.

Abstract: The present disclosure provides a carbide refining method of a high-carbon high-alloy steel. The carbide refining method of a high-carbon high-alloy steel includes the following steps: formulating a raw material according to chemical element compositions of the high-carbon high-alloy steel, and smelting to obtain a high-carbon high-alloy molten steel; performing an overheat treatment on the high-carbon high-alloy molten steel to Tm+(50˜100)° C., to obtain a high-carbon high-alloy melt, and making the high-carbon high-alloy melt to be deposited in a preset water-cooled copper mold at a speed of 30˜160 g/s by an inert gas, to obtain a high-carbon high-alloy billet through solidification molding; and performing a heat treatment process on the high-carbon high-alloy billet.

Abstract: Described herein are MK2 inhibitors of Formula (II) and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.

Abstract: Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.

Abstract: Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.